Have any questions? 706-721-6582 or cts@augusta.edu
- (MELODY) A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants
Clinical Trial
(MELODY) A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants
This study is to evaluate a longer-acting vaccine to prevent RSV (Respiratory Syncytial Virus) in healthy neonates.
Eligibility Criteria
- Inclusion Criteria: 1. Healthy pre-term and full-term infants who are entering their first RSV season Exclusion Criteria: 1. Any infants who have fever or acute illness within 7 days prior to randomization 2. Any infants who have or have a history of a lung infection or RSV infection 3.Any infant with a history of health problems 4. Children of employees of the sponsor or Augusta University
RESEARCH. INNOVATION. DISCOVERY.